Literature DB >> 27156743

Three-Dimensional Measurement of Hepatocellular Carcinoma Ablation Zones and Margins for Predicting Local Tumor Progression.

Arnaud Hocquelet1, Hervé Trillaud2, Nora Frulio2, Panteleimon Papadopoulos2, Pierre Balageas2, Cécile Salut2, Marie Meyer2, Jean-Frédéric Blanc3, Michel Montaudon4, Baudouin Denis de Senneville5.   

Abstract

PURPOSE: To propose a postprocessing technique that measures tumor surface with insufficient ablative margins (≤ 5 mm) on magnetic resonance (MR) imaging to predict local tumor progression (LTP) following radiofrequency (RF) ablation.
MATERIALS AND METHODS: A diagnostic method is proposed based on measurement of tumor surface with a margin ≤ 5 mm on MR imaging. The postprocessing technique includes fully automatic registration of pre- and post-RF ablation MR imaging, a semiautomatic segmentation of pre-RF ablation tumor and post-RF ablation volume, and a subsequent calculation of the three-dimensional exposed tumor surface area. The ability to use this surface margin ≤ 5 mm to predict local recurrence at 2 years was then tested on 16 patients with cirrhosis who were treated by RF ablation with a margin ≤ 5 mm in 2012: eight with LTP matched according to tumor size and number and α-fetoprotein level versus eight without local recurrence.
RESULTS: The error of estimated tumor surface with a margin ≤ 5 mm was less than 12%. Results of a log-rank test showed that patients with a tumor surface area > 425 mm(2) had a 2-year LTP rate of 77.5%, compared with 25% for patients with a tumor surface area ≤ 425 mm(2) (P = .018).
CONCLUSIONS: This proof-of-concept study proposes an accurate and reliable postprocessing technique to estimate tumor surface with insufficient ablative margins, and underscores the potential usefulness of tumor surface with a margin ≤ 5 mm to stratify patients with HCC treated by RF ablation according to their risk of LTP.
Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27156743     DOI: 10.1016/j.jvir.2016.02.031

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  14 in total

1.  Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression.

Authors:  Elena A Kaye; Francois H Cornelis; Elena N Petre; Neelam Tyagi; Waleed Shady; Weiji Shi; Zhigang Zhang; Stephen B Solomon; Constantinos T Sofocleous; Jeremy C Durack
Journal:  Eur Radiol       Date:  2018-11-06       Impact factor: 5.315

Review 2.  Thermal Ablation of Metastatic Colon Cancer to the Liver.

Authors:  Juan C Camacho; Elena N Petre; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

3.  F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin.

Authors:  Paul B Shyn; Alan J Cubre; Paul J Catalano; Leslie K Lee; Hyewon Hyun; Kemal Tuncali; Julia G Seol; Vincent M Levesque; Victor H Gerbaudo; Tina Kapur; Ryan T Chao; Stuart G Silverman
Journal:  Abdom Radiol (NY)       Date:  2021-02-19

4.  Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation.

Authors:  Arnaud Hocquelet; Olivier Seror; Jean-Frédéric Blanc; Nora Frulio; Cécile Salut; Jean-Charles Nault; Hervé Trillaud
Journal:  Oncotarget       Date:  2017-05-09

5.  A Novel CT to Cone-Beam CT Registration Method Enables Immediate Real-Time Intraprocedural Three-Dimensional Assessment of Ablative Treatments of Liver Malignancies.

Authors:  Marco Solbiati; Katia M Passera; S Nahum Goldberg; Alessandro Rotilio; Tiziana Ierace; Vittorio Pedicini; Dario Poretti; Luigi Solbiati
Journal:  Cardiovasc Intervent Radiol       Date:  2018-02-28       Impact factor: 2.740

6.  Safety margin assessment after microwave ablation of liver tumors: inter- and intrareader variability.

Authors:  Jan Schaible; Benedikt Pregler; Wolf Bäumler; Ingo Einspieler; Ernst-Michael Jung; Christian Stroszczynski; Lukas Philipp Beyer
Journal:  Radiol Oncol       Date:  2020-02-12       Impact factor: 2.991

Review 7.  Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria.

Authors:  Yanzhao Zhou; Yi Yang; Bingyan Zhou; Zhengzheng Wang; Ruili Zhu; Xun Chen; Jingzhong Ouyang; Qingjun Li; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-06-21

8.  Integrating interventional oncology in the treatment of liver tumors.

Authors:  D Putzer; P Schullian; E Braunwarth; M Fodor; F Primavesi; B Cardini; T Resch; R Oberhuber; M Maglione; C Margreiter; S Schneeberger; S Stättner; D Öfner-Velano; W Jaschke; R J Bale
Journal:  Eur Surg       Date:  2018-04-13       Impact factor: 0.953

Review 9.  Navigation Systems for Treatment Planning and Execution of Percutaneous Irreversible Electroporation.

Authors:  Irene Fuhrmann; Ute Probst; Philipp Wiggermann; Lukas Beyer
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

10.  Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning.

Authors:  Yi-Quan Jiang; Su-E Cao; Shilei Cao; Jian-Ning Chen; Guo-Ying Wang; Wen-Qi Shi; Yi-Nan Deng; Na Cheng; Kai Ma; Kai-Ning Zeng; Xi-Jing Yan; Hao-Zhen Yang; Wen-Jing Huan; Wei-Min Tang; Yefeng Zheng; Chun-Kui Shao; Jin Wang; Yang Yang; Gui-Hua Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-27       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.